Skip to main content


1. Fürst G, Schulte am Esch J, Poll LW, Hosch SB, Fritz LB, Klein M, Godehardt E, Krieg A, Wecker B,
Stoldt V, Stockschlûder M, Eisenberger CF, Mödder U: Portal vein ebolization and autologous CD133+
bone marrow stem cells for liver regeneration: initial experience. Radiology. 2007 Apr; 243(1):171-9.
2. Miyayama S, Matsi O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D,
Tanaka N, Mitsui T.: Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter
for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of
the portal vein with iodized oil. J Vasc Interv Radiol. 2007 Mar;18(3):365-76.
3. Asayama Y, Yoshimitsu K, Nishihara Y, Irie H, Aishima S, Taketomi A, Honda: Arterial blood supply of
hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. AJR Am J Roetgenol.
2008 Jan;190(1):W28-34
4. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM,
Bruix J: Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin
pharmacokinetics. J Hepatol. 2007 Mar; 46(3):474-81.
5. Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M.: Colorectal liver metastases: regional chemotherapy
via transarterial chemoembolisation (TACE) and hepatic chemoprfusion: an update. Eur Radiol. 2007
6. Taylor PR, Tang Y, Gonzalez MV, Stratford PW, Lewi al: Irinotecan drug eluting beads for use in
chemoembolisation: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007
Jan; 30(1):7-14.
7. Prior JO, Kosinski M, Delaloye AB, Denys A.: Initial report of PET/CT-guided radiofrequency ablation
of liver metastases. J Vasc Interv Radiol. 2007 Jun; 18(6):801-3.
8. Siperstein AE, Berber E, Ballem N, Parikh RT.: Survival after radiofrequency ablation of colorectal liver
metastases: 10-year experience. Ann Surg. 2007 Oct;246(4):559-65.
9. Sørensen SM, Mortensen FV, Nielson DT.: Radiofrequency ablation of colorectal liver metastases: long-term
survival. Acta Radiol. 2007 Apr; 48(3):253-8.
10. Josep M Llovet, Andrew Borroughs, Jordi Bruix: Hepatocellurar carcinoma Lancet 2003. 362;
December 6:1907-1917
11. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Kojiro M, Makuuchi M Yamaoka Y;
Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for
unresectable hepatocellular carcinoma in 8510 patients. Gastroenerology. 2006 Aug;131 (2):461-9
12. Abitabile P, Hartl U, Lange J, Maurer CA.: Radiofrequency ablation permits an effective treatment for
colorectal liver metastasis. Eur J Surg Oncol. 2007 Feb; 33 (1):67-71.
528 Gastro Update 2008
13. van Hooft JE, Bemelman WA, Breumelhof R, Siersema PD, Kruyt PM, van der Linde K, Veenendaal RA,
Verhulst ML, Marinelli AW, Gerritsen JJ, van Berkel AM, Timmer R, Grubben MJ, Scolten P, Geraedts
AA, Oldenburg B, Sprangers: Colonic stenting as bridge to surgey versus emergency surgery for man
agement of acute left-sided malignant colonic obstruction: a multicenter randomized trial. BMC Surg.
2007 Jul 3;7:12.
14. Tilney HS, Lovegrove RE, Purkayastha S, Sains PS, Weston-Petrides GK, Darzi AW, Tekkis PP, Heriot AG.:
Comparison of colonic stenting and open surgery for malignant large bowel struction. Surg Endosc.
2007 Feb;21 (2):225-33.
15. Siddiqui A, Khandelwal N, Anthony T, Huerta S.: Colonic stent versus surgery for the management of
acute malignant colonic obstruction:a descision analysis. Aliment Pharmacol Ther. 2007 Nov 15 ;26
16. Alcantara M, Serra X, Bombardón J, Falcó J, Perandreu J, Ayguavives I, Mora L, Hernando R, Navarro S.:
Colorectal stenting as an effective therapy for preoperative and palliative treatment of large bowel
obstruction: 9 years’ experience. Tech Coloprotocol. 2007 dec 3.
17. Govindarajan A, Naimark D, Coburn Ng, Smith AJ, Law CH.: Use of colonic stents in emergent malignant
left colonic obstruction: a Markov chain Monte Carlo decision analysis. Dis Colon Rectum. 2007 Nov,
50 (11):1811-24.
18. Small AJ, Young-Fadok TM, Baron TH.: Expandable metal stent placement for begin colorectal obstruction:
outcomes for 23 cases. Surg Endosc. 2007 Aug 18.
19. Wicherts DA, de Haas RJ, Adam R: Bringing unresectable liver disease to resection with curative intent.
Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S42-51.
20. Khatri VP, Chee KG, Petrelli NJ.: Modern multimodality approach to hepatic colorectal metastases:
solutions and controversies. Surg Oncol. 2007 Jul; 16 (1):71-83.
21. Mentha G, Majno P, Terraz S, Rubbia-Brandt L, Gervaz P, Andres A, Allal AS, Morel P, Roth AD.:
Treatment strategies for the management of advanced colorectal liver metastases detected synchronously
with the primary tumour. Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S76-83.
22. Lorentzen T, Nolsøe CP, Adamsen S.: Percutaneous radiologic gastrostomy with a simplified gastropexy
technique under ultrasonographic and fluoroscopic guidance: experience in 154 patients. Acta Radiol.
2007 Feb;48 (1):13-9.
23. MacLean AA, Alvarez NR, Davies JD, Lopez PP, Pizano LR.: Complications of percutaneous endoscopic
and fluoroscopic gastrostomy tube insertion procedures in 378 patients. Gastroenterol Nurs. 2007 SeptOkt;30
24. Cantwell CP, Gervais DA, Hanh PF, Mueller PR.: Feasibility and safety of infracolic fluoroscopically
guided perrcutaneous radiologic gasrtrostomy. J Vasc Inerv Radiol. 2008 Jan;19 (1):129-32.
25. Wiggenraad RG, Flierman L, Goossens A, Brand R, Verschuur HP, Croll GA, Moser LE, Vriesendorp R.:
Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoterapy
for advanced head and neck cancer, a preliminary study. Clin Otolaryngol. 2007 Oct;32 (5):384-90.
26. Cappell MS.: Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic
gasrtostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases.
Am J Gastroenterol. 2007 Jun;102 (6):1307-11.
27. Machi J at al.: Long-term outcome of radiofrequency ablation for unresectable liver metastases from
colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management.
Cancer J. Jul-Aug; 12(4):318-26.